For decades, pharmaceutical brands have communicated with prescribers through channels designed for someone else’s workflow — rep visits scheduled between consults, journal ads read at the end of a long week, emails buried in an inbox. The result: critical product updates often arrive long after the prescribing decision has already been made.
The shift to e-prescribing in New Zealand has changed what’s possible. With more than 50,000 prescriptions flowing through the ReScript platform every day, there is now a moment — measured in seconds — where the right clinical information can reach the right prescriber, inside the system they’re already using, at the exact point a decision is being made.
Information that arrives too late doesn’t change behaviour
Most pharmaceutical communication still operates on a “broadcast and hope” model: a campaign goes out, a rep schedules a visit, a webinar gets recorded. The challenge isn’t the quality of the information — it’s the gap between when it’s delivered and when it’s needed. By the time a GP sees a brochure about an updated dosing guideline, they may have written the prescription three weeks ago.
“The most clinically useful information in the world has no impact if it arrives after the prescription has been signed.”
From broadcast to point-of-care activation
Embedding clinical updates and product alerts directly inside the practice management system changes the economics of communication. Instead of competing for attention, the message appears in context — when a prescriber selects a relevant medication, reviews a patient’s profile, or considers a switch.
That’s the model MediActivate operates: real-time, clinical-guideline-based alerts surfaced inside the prescribing workflow, with microtargeted delivery so prescribers only see messages relevant to the patient in front of them.
What This Enables
Three outcomes pharma brands can finally measure
Targeted clinical education — guideline updates, indication changes and safety alerts reach the prescribers who actually treat the relevant patient cohorts.
Dispense-level engagement — patients receive timely SMS and email touchpoints at the pharmacy stage, supporting adherence and reducing avoidable harm.
Data-driven optimisation — anonymised, aggregate reporting lets brand teams see which messages drove engagement, where coverage is strongest, and where to invest next.
